PRA Health Sciences Inc (NASDAQ:PRAH) has received a consensus rating of “Buy” from the twelve ratings firms that are covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $113.50.
PRAH has been the topic of a number of recent analyst reports. UBS Group initiated coverage on shares of PRA Health Sciences in a report on Tuesday, October 9th. They set a “neutral” rating on the stock. BidaskClub downgraded shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 11th. Evercore ISI initiated coverage on shares of PRA Health Sciences in a report on Thursday, October 4th. They set an “inline” rating and a $120.00 price target on the stock. SunTrust Banks raised their price target on shares of PRA Health Sciences to $120.00 and gave the company a “buy” rating in a report on Monday, November 5th. Finally, Zacks Investment Research downgraded shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Price Capital Management Inc. bought a new stake in PRA Health Sciences during the 3rd quarter worth approximately $121,000. Mount Yale Investment Advisors LLC raised its stake in PRA Health Sciences by 103.6% during the 2nd quarter. Mount Yale Investment Advisors LLC now owns 1,704 shares of the medical research company’s stock worth $159,000 after acquiring an additional 867 shares during the period. Parallel Advisors LLC raised its stake in PRA Health Sciences by 930.9% during the 3rd quarter. Parallel Advisors LLC now owns 1,804 shares of the medical research company’s stock worth $199,000 after acquiring an additional 1,629 shares during the period. Bremer Trust National Association bought a new stake in PRA Health Sciences during the 3rd quarter worth approximately $205,000. Finally, Gideon Capital Advisors Inc. bought a new stake in PRA Health Sciences during the 3rd quarter worth approximately $207,000. 97.23% of the stock is currently owned by institutional investors.
PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings results on Wednesday, October 31st. The medical research company reported $1.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.07 by $0.06. The firm had revenue of $717.60 million for the quarter, compared to the consensus estimate of $729.63 million. PRA Health Sciences had a net margin of 2.37% and a return on equity of 25.75%. The business’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.88 EPS. As a group, research analysts predict that PRA Health Sciences will post 3.93 earnings per share for the current fiscal year.
About PRA Health Sciences
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.